Takada et al. [73] studied the clinical effect of probiotics in 294 patients with advanced or recurrent NSCLC treated with anti-PD-1 immunotherapy (nivolumab or pembrolizumab monotherapy). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.